Membranous Nephropathy – Epidemiology – Middle East And Africa
DRG Epidemiology’s coverage of membraneous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of MN for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered.
DRG Epidemiology’s MN forecast will answer the following questions:
How many cases of MN in the countries under study have been formally diagnosed?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MN over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following MN patient populations:
Membranous Nephropathy - Epidemiology - Middle East And Africa
Introduction
Key Updates
Key Findings
Diagnosed Incidence of Membranous Nephropathy per Year per 1,000,000 People of All Ages in 2020 and 2030
Relative Sizes of the Factors Contributing to the Trend in Diagnosed Incident Cases of Membranous Nephropathy over the Next Ten Years
Epidemiology Data
Methods
Diagnosed Incident Cases of Membranous Nephropathy
Diagnosed Lifetime Prevalent Cases of Membranous Nephropathy
Reference Materials
Literature Review
Studies Included in the Analysis of Membranous Nephropathy
Studies Excluded from the Analysis of Membranous Nephropathy
Risk/Protective Factors
Risk/Protective Factors for Membranous Nephropathy
Bibliography
Shilpa Thakur
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.
Abey John, M.P.H.
Abey John, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing family planning health programs in India in collaboration with the government of India. He also has worked at the grassroots level as a health team manager to help the rural population living in the foothills of the Himalayas. He holds a master’s degree in public health.
